Corporate Profile
To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Jun 14, 2021
Jun 10, 2021
Events
Jun 3, 2021 at 2:00 PM EDT
Jan 11, 2021 at 3:40 PM EST